The delivery of therapeutic genes for treatment of inherited or infectious diseases frequently requires lentiviral transduction of CD34+ hematopoietic stem and progenitor cells (HSC). Optimized transduction protocols with a therapeutic goal aim to maximize the number of transduction-positive cells while limiting the vector copy number that reach each individual cell. Importantly, the transduced HSC should maintain their “stem-like” properties. Here, we analyzed LentiBOOST™ reagent, a membrane-sealing poloxamer, with respect to enhancing lentiviral transduction of CD34+ peripheral blood stem cells. We demonstrate that inclusion of LentiBOOST™ in a standard HSC transduction protocol yields high transduction efficiencies while preserving the ability of the transduced HSC to differentiate into various hematopoietic lineages. Thus, LentiBOOST™ reagent can significantly improve lentiviral CD34+ HSC transduction protocols with the potential to improve production of gene-modified cell products.
WangJ, HolmesMC. Engineering hematopoietic stem cells toward a functional cure of human immunodeficiency virus infection. Cytotherapy, 2016; 18:1370–1381.
5.
KarpinskiJ, HauberI, ChemnitzJ, SchaferC, Paszkowski-RogaczM, ChakrabortyD, BeschornerN, Hofmann-SieberH, LangeUC, GrundhoffA, HackmannK, SchrockE, Abi-GhanemJ, PisabarroMT, SurendranathV, SchambachA, LindnerC, vanLJ, HauberJ, BuchholzF. Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Nat Biotechnol, 2016; 34:401–409.
6.
NeschadimA, McCartJA, KeatingA, MedinJA. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation. Biol Blood Marrow Transplant, 2007; 13:1407–1416.
7.
SchambachA, ZychlinskiD, EhrnstroemB, BaumC. Biosafety features of lentiviral vectors. Hum Gene Ther, 2013; 24:132–142.
8.
MillingtonM, ArndtA, BoydM, ApplegateT, ShenS. Towards a clinically relevant lentiviral transduction protocol for primary human CD34 hematopoietic stem/progenitor cells. PLoS One, 2009; 4: e6461.
9.
IngraoD, MajdoulS, SeyeAK, GalyA, FenardD. Concurrent measures of fusion and transduction efficiency of primary CD34+ cells with human immunodeficiency virus 1-based lentiviral vectors reveal different effects of transduction enhancers. Hum Gene Ther Methods, 2014; 25:48–56.
10.
FenardD, IngraoD, SeyeA, BuissetJ, GenriesS, MartinS, KichlerA, GalyA. Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells. Mol Ther Nucleic Acids, 2013; 2:e90.
11.
AubinRJ, WeinfeldM, PatersonMC. Factors influencing efficiency and reproducibility of polybrene-assisted gene transfer. Somat Cell Mol Genet, 1988; 14:155–167.
12.
LinP, CorreaD, LinY, CaplanAI. Polybrene inhibits human mesenchymal stem cell proliferation during lentiviral transduction. PLoS One, 2011; 6:e23891.
13.
CornettaK, AndersonWF. Protamine sulfate as an effective alternative to polybrene in retroviral-mediated gene-transfer: implications for human gene therapy. J Virol Methods, 1989; 23:187–194.
14.
VogtPK. DEAE-dextran: enhancement of cellular transformation induced by avian sarcoma viruses. Virology, 1967; 33:175–177.
15.
WurmM, SchambachA, LindemannD, HanenbergH, StandkerL, ForssmannWG, BlasczykR, HornPA. The influence of semen-derived enhancer of virus infection on the efficiency of retroviral gene transfer. J Gene Med, 2010; 12:137–146.
16.
YolamanovaM, MeierC, ShaytanAK, VasV, BertonciniCW, ArnoldF, ZirafiO, UsmaniSM, MullerJA, SauterD, GoffinetC, PaleschD, WaltherP, RoanNR, GeigerH, LunovO, SimmetT, BohneJ, SchrezenmeierH, SchwarzK, StandkerL, ForssmannWG, SalvatellaX, KhalaturPG, KhokhlovAR, KnowlesTP, WeilT, KirchhoffF, MunchJ. Peptide nanofibrils boost retroviral gene transfer and provide a rapid means for concentrating viruses. Nat Nanotechnol, 2013; 8:130–136.
LeeRC, RiverLP, PanFS, JiL, WollmannRL. Surfactant-induced sealing of electropermeabilized skeletal muscle membranes in vivo. Proc Natl Acad Sci U S A, 1992; 89:4524–4528.
19.
Singh-JoySD, McLainVC. Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. Int J Toxicol, 2008; 27Suppl 2:93–128.
20.
DullT, ZuffereyR, KellyM, MandelRJ, NguyenM, TronoD, NaldiniL. A third-generation lentivirus vector with a conditional packaging system. J Virol, 1998; 72:8463–8471.
21.
BeyerWR, WestphalM, OstertagW, von LaerD. Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J Virol, 2002; 76:1488–1495.
22.
O'DohertyU, SwiggardWJ, MalimMH. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol, 2000; 74:10074–10080.
LanutiM, KouriCE, ForceS, ChangM, AminK, XuK, BlairI, KaiserL, AlbeldaS. Use of protamine to augment adenovirus-mediated cancer gene therapy. Gene Ther, 1999; 6:1600–1610.
25.
YangYW, HsiehYC. Protamine sulfate enhances the transduction efficiency of recombinant adeno-associated virus-mediated gene delivery. Pharm Res, 2001; 18:922–927.
26.
CarrollD. Genome engineering with targetable nucleases. Annu Rev Biochem, 2014; 83:409–439.
27.
MaederML, GersbachCA. Genome-editing technologies for gene and cell therapy. Mol Ther, 2016; 24:430–446.
28.
MeinkeG, BohmA, HauberJ, PisabarroMT, BuchholzF. Cre Recombinase and other tyrosine recombinases. Chem Rev, 2016; 116:12785–12820.
29.
SokolowskaE, KalaskaB, MikloszJ, MogielnickiA. The toxicology of heparin reversal with protamine: past, present and future. Expert Opin Drug Metab Toxicol, 2016; 12:897–909.
30.
LinP, LinY, LennonDP, CorreaD, SchluchterM, CaplanAI. Efficient lentiviral transduction of human mesenchymal stem cells that preserves proliferation and differentiation capabilities. Stem Cells Transl Med, 2012; 1:886–897.
31.
ChuahMK, VanDA, ZwinnenH, GoovaertsI, VanslembrouckV, CollenD, VandenDriesscheT. Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. Hum Gene Ther, 2000; 11:729–738.
32.
ShubhraQTH, TóthJ, GyenisJ, FeczkóhuahT. Poloxamers for surface modification of hydrophobic drug carriers and their effects on drug delivery. Polym Rev, 2014; 54:112–138.
33.
DiGiustoDL, CannonPM, HolmesMC, LiL, RaoA, WangJianbin, LeeGary, PhilipD. Gregory,Kenneth A Kim, Samuel B Hayward, Kathleen Meyer,Colin Exline, Evan Lopez, Jill Henley, Nancy Gonzalez,Victoria Bedell, Rodica Stan, John A Zaia. Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells. Mol Ther Methods Clin Dev, 2016; 3:16067.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
